Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | NMUR2 | Q9GZQ4 | 7/20 | 0.58 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29474228 | 1.00 | F2 (0.59) | F2NMUR2NMUR1OPRD1OPRM1 | |
| SCHEMBL29566266 | 0.92 | OPRD1 (0.61) | F2NMUR2NMUR1OPRD1OPRM1 | |
| SCHEMBL30312765 | 0.92 | OPRM1 (0.58) | NMUR2NMUR1OPRM1OPRK1 | |
| Substance P SCHEMBL29831869 | 0.84 | OPRD1 (0.67) | F2NMUR2NMUR1OPRD1OPRM1 | |
| Substance P SCHEMBL1116347 | 0.84 | OPRD1 (0.67) | F2NMUR2NMUR1OPRD1OPRM1 | |
| SCHEMBL29498256 | 0.84 | OPRD1 (0.67) | F2NMUR2NMUR1OPRD1OPRM1 | |
| Substance P SCHEMBL18769078 | 0.84 | OPRD1 (0.67) | F2NMUR2NMUR1OPRD1OPRM1 | |
| Substance P SCHEMBL19057679 | 0.84 | OPRD1 (0.67) | F2NMUR2NMUR1OPRD1OPRM1 | |
| Substance P SCHEMBL17887651 | 0.84 | OPRD1 (0.67) | F2NMUR2NMUR1OPRD1OPRM1 | |
| SCHEMBL30312784 | 0.84 | OPRM1 (0.60) | NMUR2NMUR1OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381199-A1 | PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN | LILLY CO ELI (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250295587-A1 | COMPLEX LIPID NANOPARTICLES ENCAPSULATING POLYPEPTIDES AND USES THEREOF | SAIL BIOMEDICINES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12329762-B2 | Pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin | ELI LILLY AND COMPANY (US) | 2025-06-17 | — | — | US | disclosed |
| US-12258377-B2 | Anti-tumour response to modified self-epitopes | SCANCELL LIMITED (GB) | 2025-03-25 | — | — | US | disclosed |
| US-20240398884-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-3509596-B1 | NORKETOTIFEN FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTIONS | EMERGO THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3328388-B1 | A PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN | LILLY CO ELI (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11819508-B2 | Miltefosine for the treatment of viral infections including covid-19 | PROFOUNDA HEALTH AND BEAUTY INC. (US) | 2023-11-21 | — | — | US | disclosed |
| EP-4275761-A2 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS | Theriva Biologics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230310558-A1 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS | THERIVA BIOLOGICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230192790-A1 | ANTI-TUMOUR RESPONSE TO MODIFIED SELF-EPITOPES | SCANCELL LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| EP-3773686-B1 | ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS | THERIVA BIOLOGICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230158043-A1 | PHARMACEUTICAL PREPARATION FOR IMPROVING ABSORPTION AND POSTPRANDIAL HYPOGLYCEMIC ACTION OF INSULIN | ELI LILLY AND COMPANY | 2023-05-25 | — | — | US | disclosed |
| US-11654184-B2 | Alkaline phosphatase agents for treatment of radiation disorders | THERIVA BIOLOGICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-3206708-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RADIATION-RELATED DISORDERS | CLEVELAND BIOLABS INC (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20220288150-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-09-15 | — | — | US | disclosed |
| US-11382985-B2 | Anti-tumour immune responses to modified self-epitopes | SCANCELL LIMITED (GB) | 2022-07-12 | — | — | US | disclosed |
| US-20220152139-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-05-19 | — | — | US | disclosed |
| US-20220072016-A1 | MILTEFOSINE FOR THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 | PROFOUNDA HEALTH AND BEAUTY INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220024991-A1 | ENGINEERED FLAGELLIN-DERIVED COMPOSITIONS AND USES | GENOME PROT INC (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072016-A1 | MILTEFOSINE FOR THE TREATMENT OF VIRAL INFECTIONS INCLUDING COVID-19 | ACE, ACE2, BDKRB2 | F2 16/4885NMUR2 1022/4885NMUR1 1107/4885 |
| US-11819508-B2 | Miltefosine for the treatment of viral infections including covid-19 | ACE, ACE2, BDKRB2 | F2 16/4885NMUR2 1022/4885NMUR1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.